Anti-Microbial Savior BioteQ , Ltd Profit Margin

Anti-Microbial Savior BioteQ , Ltd posts a profit margin of -9826.23% as of June 2026. That compares with -4283.76% in the prior-year period — down 129.4% year over year. That is below the Healthcare sector average of 9.48%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Anti-Microbial Savior BioteQ , Ltd's profit margin was -4283.76%. The latest reading is -9826.23% — a 129.4% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 9.48% is typical. Anti-Microbial Savior BioteQ , Ltd's -9826.23% is lower that level. That is roughly 103741.6% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Anti-Microbial Savior BioteQ , Ltd's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -9826.23% as of June 2026; use YoY and peer views to separate noise from signal.

Context for 6864.TWO's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 9.48%), and (3) consistency with growth and profitability. This page covers the first two; Anti-Microbial Savior BioteQ , Ltd's other metric pages and overview cover the third.